argenx is running clinical trials of efgartigimod, an investigational FcRn antagonist

Our Commitment to Patients

Each day at argenx, we are motivated to pursue a better tomorrow alongside patients. We aim to do this through partnership because we know that "together we are better". As your ally, we pioneer innovations to advance the understanding of rare diseases; we want to deliver immunology treatments to patients worldwide.

We listen to patients, supporters and advocacy communities; we hear your stories and share your determination.

We integrate your aspirations into how we innovate, how we conduct research and design trials, and how we can support you in the daily struggles you face living with a rare disease.

There is a common purpose across argenx that is driven by your resilience and we welcome this opportunity to be with you on this journey.

Clinical Trials

argenx is running clinical trials of efgartigimod, an investigational FcRn antagonist that is in development for severe autoimmune diseases.